- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00991510
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Comparative Bioavailability of Myfenax® (Teva) and CellCept® (Roche) in Stable Patients After Renal Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Renal transplant recipients at least 12 months post-transplantation aged ≥ 18 years.
- Maintenance treatment with mycophenolate mofetil (in combination with tacrolimus with or without corticosteroids).
- Stable dose of mycophenolate mofetil (≥ 500 mg twice daily) with no changes in immunosuppressive regimen for at least 6 weeks prior to the start of the study.
- Stable renal graft function for at least 3 months.
- Female patients must be either post-menopausal for ≥ 1 year, be surgically sterilized or a negative pregnancy test will be required immediately prior to study entry and such patients must continue to use effective contraception.
- Willingness to undergo the study-related procedures.
- Ability to comprehend and willingness to sign informed consent form.
Exclusion Criteria:
- History of allergy to mycophenolate mofetil, mycophenolic acid or any of the ingredients.
- Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any organ other than kidney.
- Rejection within the past 6 months prior to the start of the study.
- Severe clinically relevant co-existing disease.
- History of cancer other than skin cancer that has been cured.
- History of serious clinically relevant digestive system disease during the last 12 months prior to start of the study.
- Known or suspected hereditary deficiency of hypoxanthine-guanine-phosphoribosyltransferase (e.g., Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome).
- Known or suspected liver impairment.
- Clinically significant thrombocytopenia, anaemia, leukopenia, or neutropenia
- Clinically significant laboratory and/or physical changes during the last 2 months prior to the start of the study.
- Use of azathioprine, cholestyramine, sevelamer, or probenecid within 2 weeks prior to the first administration of study medication.
- Change in concomitant medication during the 6 weeks prior to start of the study.
- Use of any drug, prescribed or over-the-counter, (except stable concomitant medication) within 2 weeks prior to the first administration of study medication.
- Planned or expected requirement for the use of live attenuated vaccines during the study.
- Positive testing for HIV, Hepatitis B and C.
- Clinical symptoms or laboratory evidence of cytomegalovirus infection in the last 6 month.
- Pregnant or breast-feeding women.
- Women of childbearing potential unable or unwilling to practice effective contraceptive measures for the duration of the study and for 6 weeks after the end of the study.
- History of known or suspected alcohol or drug abuse.
- Any other condition of the patient that, in the opinion of the investigator may compromise evaluation of the study treatment or may jeopardize patient's compliance or adherence to protocol requirements.
- Previous enrollment in this study or participation in any other drug investigational trial within the past 6 weeks prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reference/Test/Test
The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112). Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening. |
Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug).
Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Other Names:
Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug).
Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Other Names:
|
Experimental: Test/Reference/Reference
The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112). Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening. |
Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug).
Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Other Names:
Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug).
Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Plasma Concentration-time Curve (AUC(0-6h)) of Mycophenolate Mofetil
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Area under the plasma concentration-time curve during a dosage interval at steady state (calculated using the trapezoidal rule, from t = 0 to t = 6 hours).
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Area Under the Plasma Concentration-time Curve (AUC(0-tau)) of Mycophenolate Mofetil
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
For participants with a 0-12h profile: Area under the plasma concentration-time curve during a dosage interval at steady state (calculated using the trapezoidal rule, from t = 0 to t = 12 hours).
For participants with a 0-6h profile: AUC(0-tau) was calculated based on AUC(0-6h) using the extrapolation formula according to Fleming.
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Maximum Observed Plasma Concentration (Cmax) of Mycophenolate Mofetil
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Cmax was directly obtained from measured values of plasma concentrations.
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimum Observed Plasma Concentration (Cmin) of Mycophenolate Mofetil
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Cmin was directly obtained from measured values of plasma concentrations.
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration and at 30 min, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug administration
|
Plasma Concentrations of Mycophenolate Mofetil in Pre-Administration Samples (Cpd)
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration
|
Cpd was directly obtained from measured values of plasma concentrations.
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration
|
Degree of Fluctuation of the Concentration Levels of Mycophenolate Mofetil Over One Dosing Interval (PTF)
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration
|
PTF was calculated as: (Cmax-Cmin)/(AUCt/t)*100
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration
|
Time Corresponding to Occurrence of Cmax (Tmax) of Mycophenolate Mofetil
Time Frame: Day 14 and Day 28 (end of first two cross-over periods) before drug administration
|
Tmax was directly obtained from measured values.
|
Day 14 and Day 28 (end of first two cross-over periods) before drug administration
|
Summary of Participants With Adverse Events
Time Frame: Day 1 up to Day 112
|
Summary of adverse events across three study time periods. The on-treatment time frame spanned the time during which study drug was administered. Relation to study drug was assessed by the investigator. The Adverse Event count includes serious and non-serious AEs. A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event could have jeopardized the patient's safety or required medical or surgical intervention to prevent one of the outcomes listed above. Severity was measured on a three-point scale: mild, moderate, severe. |
Day 1 up to Day 112
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gere Sunder-Plassman, Prof.,MD, Medical University Vienna
Publications and helpful links
General Publications
- Sunder-Plassmann G et al.: Results of a Comparative Bioavailability Study of Myfenax (Teva) and CellCept (Roche) in Stable Kidney Transplant Recipients. American Transplant Congress 2011. Abstract Number: 250308
- Sunder-Plassmann G, Reinke P, Rath T, Wiecek A, Nowicki M, Moore R, Lutz J, Gaggl M, Ferkl M. Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. Transpl Int. 2012 Jun;25(6):680-6. doi: 10.1111/j.1432-2277.2012.01475.x. Epub 2012 Apr 16.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116B8
- 2009-010562-31 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stable Renal Transplant Recipients
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Universidade Federal de PernambucoUnknownRenal Transplant RecipientsBrazil
-
Lawson Health Research InstituteAstellas Pharma Canada, Inc.CompletedRenal Transplant RecipientsCanada
-
Astellas Pharma China, Inc.CompletedRenal Transplant RecipientsChina
-
Georgetown UniversityTerminatedRenal Transplant RecipientsUnited States
-
Agency for Healthcare Research and Quality (AHRQ)Unknown
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedRenal Transplant RecipientsUnited States
-
Montefiore Medical CenterTerminated
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
Clinical Trials on mycophenolate mofetil (Myfenax)
-
University of GiessenNovartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg UniversityCompletedPolyomavirus InfectionsGermany
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States
-
Nanjing University School of MedicineCompletedNephritis | Henoch-Schoenlein PurpuraChina
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...WithdrawnSteroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeChina
-
Nanjing University School of MedicineCompletedVasculitis | Anti-Neutrophil Cytoplasmic AntibodyChina
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Fred Hutchinson Cancer CenterUniversity of WashingtonCompleted
-
Samsung Medical CenterUnknown
-
Hoffmann-La RocheAspreva PharmaceuticalsCompletedPemphigus Vulgaris (PV)Turkey, Switzerland, United States, Germany, United Kingdom, Ukraine, Israel, Canada